Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00146289 |
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
Condition | Intervention | Phase |
---|---|---|
Obesity Insulin Resistance |
Drug: MICARDIS® (telmisartan) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Randomised, DB, Placebo-Controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-Concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-Diabetic, Normotensive, Using the OGTT, With a Clamp Sub-Group |
Estimated Enrollment: | 120 |
Study Start Date: | February 2005 |
Estimated Study Completion Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
Pre-menopausal women (last menstruation <=1 year prior to signing informed consent) who:
United States, California | |
UCLA School of Medicine- Divison of Endocrinology | |
Los Angeles, California, United States | |
University of CA at SanDiego- Department of Endocrinology | |
San Diego, California, United States | |
Boehringer Ingelheim Investigational Site | |
Westlake Village, California, United States | |
United States, Illinois | |
Boehringer Ingelheim Investigational Site | |
Chicago, Illinois, United States | |
United States, New York | |
University of Rochester Medical Center | |
Rochester, New York, United States | |
United States, Ohio | |
Boehringer Ingelheim Investigational Site | |
Cincinnati, Ohio, United States | |
United States, Tennessee | |
Boehringer Ingelheim Investigational Site | |
Nashville, Tennessee, United States | |
United States, Texas | |
Boehringer Ingelheim Investigational Site | |
Harker Heights, Texas, United States | |
Canada, Manitoba | |
University of Manitoba, Diabetes Research Group | |
Winnipeg, Manitoba, Canada | |
Canada, Ontario | |
St. Joseph's Health Care London | |
London, Ontario, Canada | |
The Ottawa Hospital - Riverside Campus | |
Ottawa, Ontario, Canada | |
Denmark | |
Århus Sygehus | |
Aarhus C, Denmark | |
Germany | |
Boehringer Ingelheim Investigational Site | |
Unterschneidheim, Germany | |
Boehringer Ingelheim Investigational Site | |
Künzing, Germany | |
Universitätsmedizin Berlin | |
Berlin, Germany | |
Italy | |
Policlinico Monteluce | |
PERUGIA, Italy | |
Azienda Ospedale Università di Pisa | |
PISA, Italy |
Study Chair: | Boehringer Ingelheim Study Coordinator | Boehringer Ingelheim Pharmaceuticals |
Study ID Numbers: | 502.469 |
Study First Received: | September 2, 2005 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00146289 |
Health Authority: | United States: Food and Drug Administration |
Obesity Metabolic Diseases Overweight Angiotensin II Insulin Body Weight Hyperinsulinism |
Signs and Symptoms Nutrition Disorders Overnutrition Insulin Resistance Telmisartan Glucose Metabolism Disorders Metabolic disorder |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Angiotensin-Converting Enzyme Inhibitors |
Enzyme Inhibitors Pharmacologic Actions Protease Inhibitors |